Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

(2010) Walter M. Stadler et al.   CANCER

The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations

(2009) Joaquim Bellmunt et al.   BJU INTERNATIONAL

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

(2009) Martin E Gore et al.   LANCET ONCOLOGY

Renal surgery in the elderly: morbidity in patients aged >75 years in a contemporary series

(2008) Michael Staehler et al.   BJU INTERNATIONAL

Performance status and cytoreductive nephrectomy

(2008) Brian Shuch et al.   CANCER

The medical treatment of metastatic renal cell cancer in the elderly: Position paper of a SIOG Taskforce

(2008) Joaquim Bellmunt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib

(2008) Natascha A.J.B. Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial

(2008) T. Eisen et al.   JNCI-Journal of the National Cancer Institute